The scientists of the Ural Federal University (UrFU) won an open tender held by the Ministry of Education and Science of the Russian Federation to develop a diabetes medication.
Mikhail Varaksin, the Associate Professor at the Department of Organic and Biomolecular Chemistry of the Institute of Chemical Engineering of UrFU, said that, currently, the pharmacotherapy of diabetes is associated with the normalization of glucose level in the blood plasma, although the most important etiopathogenetic factor in the development of late complications of this disease is the formation of advanced glycation end-products in the process of non-enzymatic glycosylation (glycation) of proteins (Maillard reaction).
“There are no medicinal products approved for clinical use that have similar mechanism of pharmacological action,” said Mikhail Varaksin. “In this regard, the development of medications that limit the formation of advanced glycation end-products (AGE) in long-lived proteins, in particular, collagen, and prevent their interaction with specific receptors (RAGE) and, as a result, block the main pathogenetic pathways for the development of late complications of diabetes (diabetic nephropathy, neuropathy, cardiomyopathy), is an extremely urgent task that has a great social and economic importance.” The implementation of the project involves preclinical studies of the medication that acts on the collagen glycation end-products and their receptors to prevent and treat the complications of diabetes.
The total funding for the project will amount to 44 million rubles, including 33 million rubles allocated from the federal budget. The remaining 11 million rubles will be provided through extra-budgetary funding. The contract implementation is scheduled for in 2017-2019. Volgograd State Medical University will act as a co-contractor of the project.